BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cui X, Ye L, Li J, Jin L, Wang W, Li S, Bao M, Wu S, Li L, Geng B, Zhou X, Zhang J, Cai J. Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients. Sci Rep 2018;8:635. [PMID: 29330424 DOI: 10.1038/s41598-017-18756-2] [Cited by in Crossref: 99] [Cited by in F6Publishing: 89] [Article Influence: 24.8] [Reference Citation Analysis]
Number Citing Articles
1 Yoshida N, Yamashita T, Hirata KI. Gut Microbiome and Cardiovascular Diseases. Diseases 2018;6:E56. [PMID: 29966270 DOI: 10.3390/diseases6030056] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
2 Chang P, Lei S, Zhang X, Zhang J, Wang X, Wu J, Wang J, Geng J, Chen B, Yu J. Metabonomics Analysis of Myocardial Metabolic Dysfunction in Patients with Cardiac Natriuretic Peptide Resistance. Cardiol Res Pract 2020;2020:1416945. [PMID: 33376601 DOI: 10.1155/2020/1416945] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Cheng WL, Li SJ, Lee TI, Lee TW, Chung CC, Kao YH, Chen YJ. Sugar Fructose Triggers Gut Dysbiosis and Metabolic Inflammation with Cardiac Arrhythmogenesis. Biomedicines 2021;9:728. [PMID: 34201938 DOI: 10.3390/biomedicines9070728] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Yadav M, Chauhan NS. Overview of the rules of the microbial engagement in the gut microbiome: a step towards microbiome therapeutics. J Appl Microbiol 2021;130:1425-41. [PMID: 33022786 DOI: 10.1111/jam.14883] [Cited by in Crossref: 9] [Article Influence: 4.5] [Reference Citation Analysis]
5 Cho MS, Kim SY, Suk KT, Kim BY. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics. J Microbiol. 2018;56:855-867. [PMID: 30377993 DOI: 10.1007/s12275-018-8346-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
6 Murphy K, O'Donovan AN, Caplice NM, Ross RP, Stanton C. Exploring the Gut Microbiota and Cardiovascular Disease. Metabolites 2021;11:493. [PMID: 34436434 DOI: 10.3390/metabo11080493] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sawicka-śmiarowska E, Moniuszko-malinowska A, Kamiński KA. Why Do These Microbes Like Me and How Could There Be a Link with Cardiovascular Risk Factors? JCM 2022;11:599. [DOI: 10.3390/jcm11030599] [Reference Citation Analysis]
8 Vlasov AA, Salikova SP, Golovkin NV, Grinevich VB. Intestinal Microbial-tissue Complex and Chronic Heart Failure (part 1): Pathogenesis. Racionalʹnaâ farmakoterapiâ v kardiologii 2021;17:462-9. [DOI: 10.20996/1819-6446-2021-06-12] [Reference Citation Analysis]
9 Albert CL, Tang WHW. Following the Scent of Microbes Within: The Heart-Gut Connection. J Card Fail 2019;25:328-9. [PMID: 30926393 DOI: 10.1016/j.cardfail.2019.03.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
10 Carrillo-Salinas FJ, Anastasiou M, Ngwenyama N, Kaur K, Tai A, Smolgovsky SA, Jetton D, Aronovitz M, Alcaide P. Gut dysbiosis induced by cardiac pressure overload enhances adverse cardiac remodeling in a T cell-dependent manner. Gut Microbes 2020;12:1-20. [PMID: 33103561 DOI: 10.1080/19490976.2020.1823801] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 12.0] [Reference Citation Analysis]
11 Chen X, Li HY, Hu XM, Zhang Y, Zhang SY. Current understanding of gut microbiota alterations and related therapeutic intervention strategies in heart failure. Chin Med J (Engl) 2019;132:1843-55. [PMID: 31306229 DOI: 10.1097/CM9.0000000000000330] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
12 Tsai HJ, Tsai WC, Hung WC, Hung WW, Chang CC, Dai CY, Tsai YC. Gut Microbiota and Subclinical Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus. Nutrients 2021;13:2679. [PMID: 34444839 DOI: 10.3390/nu13082679] [Reference Citation Analysis]
13 Dubinski P, Czarzasta K, Cudnoch-Jedrzejewska A. The Influence of Gut Microbiota on the Cardiovascular System Under Conditions of Obesity and Chronic Stress. Curr Hypertens Rep 2021;23:31. [PMID: 34014393 DOI: 10.1007/s11906-021-01144-7] [Reference Citation Analysis]
14 Doran S, Arif M, Lam S, Bayraktar A, Turkez H, Uhlen M, Boren J, Mardinoglu A. Multi-omics approaches for revealing the complexity of cardiovascular disease. Brief Bioinform 2021:bbab061. [PMID: 33725119 DOI: 10.1093/bib/bbab061] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Fromentin S, Forslund SK, Chechi K, Aron-Wisnewsky J, Chakaroun R, Nielsen T, Tremaroli V, Ji B, Prifti E, Myridakis A, Chilloux J, Andrikopoulos P, Fan Y, Olanipekun MT, Alves R, Adiouch S, Bar N, Talmor-Barkan Y, Belda E, Caesar R, Coelho LP, Falony G, Fellahi S, Galan P, Galleron N, Helft G, Hoyles L, Isnard R, Le Chatelier E, Julienne H, Olsson L, Pedersen HK, Pons N, Quinquis B, Rouault C, Roume H, Salem JE, Schmidt TSB, Vieira-Silva S, Li P, Zimmermann-Kogadeeva M, Lewinter C, Søndertoft NB, Hansen TH, Gauguier D, Gøtze JP, Køber L, Kornowski R, Vestergaard H, Hansen T, Zucker JD, Hercberg S, Letunic I, Bäckhed F, Oppert JM, Nielsen J, Raes J, Bork P, Stumvoll M, Segal E, Clément K, Dumas ME, Ehrlich SD, Pedersen O. Microbiome and metabolome features of the cardiometabolic disease spectrum. Nat Med 2022;28:303-14. [PMID: 35177860 DOI: 10.1038/s41591-022-01688-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Katsimichas T, Antonopoulos AS, Katsimichas A, Ohtani T, Sakata Y, Tousoulis D. The intestinal microbiota and cardiovascular disease. Cardiovascular Research 2019;115:1471-86. [DOI: 10.1093/cvr/cvz135] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
17 Sharma R. Emerging Interrelationship Between the Gut Microbiome and Cellular Senescence in the Context of Aging and Disease: Perspectives and Therapeutic Opportunities. Probiotics Antimicrob Proteins 2022. [PMID: 34985682 DOI: 10.1007/s12602-021-09903-3] [Reference Citation Analysis]
18 Cui Y, Chang R, Zhang T, Zhou X, Wang Q, Gao H, Hou L, Loor JJ, Xu C. Chinese Herbal Formula (CHF03) Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) Through Inhibiting Lipogenesis and Anti-Oxidation Mechanisms. Front Pharmacol 2019;10:1190. [PMID: 31680967 DOI: 10.3389/fphar.2019.01190] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
19 Sharma SP, Suk KT, Kim DJ. Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases. World J Gastroenterol 2021; 27(37): 6161-6179 [PMID: 34712025 DOI: 10.3748/wjg.v27.i37.6161] [Reference Citation Analysis]
20 Guan H, Pu Y, Liu C, Lou T, Tan S, Kong M, Sun Z, Mei Z, Qi Q, Quan Z, Zhao G, Zheng Y. Comparison of Fecal Collection Methods on Variation in Gut Metagenomics and Untargeted Metabolomics. mSphere 2021;6:e0063621. [PMID: 34523982 DOI: 10.1128/mSphere.00636-21] [Reference Citation Analysis]
21 Li L, Zhong S, Cheng B, Qiu H, Hu Z. Cross-Talk between Gut Microbiota and the Heart: A New Target for the Herbal Medicine Treatment of Heart Failure? Evid Based Complement Alternat Med 2020;2020:9097821. [PMID: 32328141 DOI: 10.1155/2020/9097821] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
22 Fei N, Bernabé BP, Lie L, Baghdan D, Bedu-Addo K, Plange-Rhule J, Forrester TE, Lambert EV, Bovet P, Gottel N, Riesen W, Korte W, Luke A, Kliethermes SA, Layden BT, Gilbert JA, Dugas LR. The human microbiota is associated with cardiometabolic risk across the epidemiologic transition. PLoS One 2019;14:e0215262. [PMID: 31339887 DOI: 10.1371/journal.pone.0215262] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
23 Guo Y, Zou J, Xu X, Zhou H, Sun X, Wu L, Zhang S, Zhong X, Xiong Z, Lin Y, Huang Y, Du Z, Liao X, Zhuang X. Short-chain fatty acids combined with intronic DNA methylation of HIF3A: Potential predictors for diabetic cardiomyopathy. Clin Nutr 2021;40:3708-17. [PMID: 34130016 DOI: 10.1016/j.clnu.2021.04.007] [Reference Citation Analysis]
24 Wang Z, Cai Z, Ferrari MW, Liu Y, Li C, Zhang T, Lyu G. The Correlation between Gut Microbiota and Serum Metabolomic in Elderly Patients with Chronic Heart Failure. Mediators Inflamm 2021;2021:5587428. [PMID: 34744513 DOI: 10.1155/2021/5587428] [Reference Citation Analysis]
25 Bastin M, Andreelli F. The gut microbiota and diabetic cardiomyopathy in humans. Diabetes Metab 2020;46:197-202. [PMID: 31678397 DOI: 10.1016/j.diabet.2019.10.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
26 Carley AN, Maurya SK, Fasano M, Wang Y, Selzman CH, Drakos SG, Lewandowski ED. Short-Chain Fatty Acids Outpace Ketone Oxidation in the Failing Heart. Circulation 2021;143:1797-808. [PMID: 33601938 DOI: 10.1161/CIRCULATIONAHA.120.052671] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Reddy Kv C. Heart-gut axis: Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) to prevent cardiovascular disease through gut microbiota. Medicine in Microecology 2021;7:100033. [DOI: 10.1016/j.medmic.2021.100033] [Reference Citation Analysis]
28 An N, Zhang G, Li Y, Yuan C, Yang F, Zhang L, Gao Y, Xing Y. Promising Antioxidative Effect of Berberine in Cardiovascular Diseases. Front Pharmacol 2022;13:865353. [DOI: 10.3389/fphar.2022.865353] [Reference Citation Analysis]
29 Zhang X, Liu H, Gao J, Zhu M, Wang Y, Jiang C, Xu M. Metabolic disorder in the progression of heart failure. Sci China Life Sci 2019;62:1153-67. [DOI: 10.1007/s11427-019-9548-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
30 Oniszczuk A, Oniszczuk T, Gancarz M, Szymańska J. Role of Gut Microbiota, Probiotics and Prebiotics in the Cardiovascular Diseases. Molecules 2021;26:1172. [PMID: 33671813 DOI: 10.3390/molecules26041172] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
31 Wu H, Chiou J. Potential Benefits of Probiotics and Prebiotics for Coronary Heart Disease and Stroke. Nutrients 2021;13:2878. [PMID: 34445037 DOI: 10.3390/nu13082878] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Liu L, Su J, Li R, Luo F. Changes in Intestinal Flora Structure and Metabolites Are Associated With Myocardial Fibrosis in Patients With Persistent Atrial Fibrillation. Front Nutr 2021;8:702085. [PMID: 34497820 DOI: 10.3389/fnut.2021.702085] [Reference Citation Analysis]
33 Almeida D, Machado D, Andrade JC, Mendo S, Gomes AM, Freitas AC. Evolving trends in next-generation probiotics: a 5W1H perspective. Crit Rev Food Sci Nutr. 2020;60:1783-1796. [PMID: 31062600 DOI: 10.1080/10408398.2019.1599812] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
34 Parker BJ, Wearsch PA, Veloo ACM, Rodriguez-Palacios A. The Genus Alistipes: Gut Bacteria With Emerging Implications to Inflammation, Cancer, and Mental Health. Front Immunol 2020;11:906. [PMID: 32582143 DOI: 10.3389/fimmu.2020.00906] [Cited by in Crossref: 65] [Cited by in F6Publishing: 71] [Article Influence: 32.5] [Reference Citation Analysis]
35 Li Q, Gao B, Siqin B, He Q, Zhang R, Meng X, Zhang N, Zhang N, Li M. Gut Microbiota: A Novel Regulator of Cardiovascular Disease and Key Factor in the Therapeutic Effects of Flavonoids. Front Pharmacol 2021;12:651926. [PMID: 34220497 DOI: 10.3389/fphar.2021.651926] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Aryal S, Alimadadi A, Manandhar I, Joe B, Cheng X. Machine Learning Strategy for Gut Microbiome-Based Diagnostic Screening of Cardiovascular Disease. Hypertension 2020;76:1555-62. [PMID: 32909848 DOI: 10.1161/HYPERTENSIONAHA.120.15885] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
37 Leon-Mimila P, Wang J, Huertas-Vazquez A. Relevance of Multi-Omics Studies in Cardiovascular Diseases. Front Cardiovasc Med 2019;6:91. [PMID: 31380393 DOI: 10.3389/fcvm.2019.00091] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 11.0] [Reference Citation Analysis]
38 Khannous-Lleiffe O, Willis JR, Saus E, Cabrera-Aguilera I, Almendros I, Farré R, Gozal D, Farré N, Gabaldón T. A Mouse Model Suggests That Heart Failure and Its Common Comorbidity Sleep Fragmentation Have No Synergistic Impacts on the Gut Microbiome. Microorganisms 2021;9:641. [PMID: 33808770 DOI: 10.3390/microorganisms9030641] [Reference Citation Analysis]
39 Xu J, Yang Y. Gut microbiome and its meta-omics perspectives: profound implications for cardiovascular diseases. Gut Microbes 2021;13:1936379. [PMID: 34170211 DOI: 10.1080/19490976.2021.1936379] [Reference Citation Analysis]
40 Jia Q, Li H, Zhou H, Zhang X, Zhang A, Xie Y, Li Y, Lv S, Zhang J. Role and Effective Therapeutic Target of Gut Microbiota in Heart Failure. Cardiovasc Ther 2019;2019:5164298. [PMID: 31819762 DOI: 10.1155/2019/5164298] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
41 Reiman D, Layden BT, Dai Y. MiMeNet: Exploring microbiome-metabolome relationships using neural networks. PLoS Comput Biol 2021;17:e1009021. [PMID: 33999922 DOI: 10.1371/journal.pcbi.1009021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Livshits G, Kalinkovich A. Inflammaging as a common ground for the development and maintenance of sarcopenia, obesity, cardiomyopathy and dysbiosis. Ageing Research Reviews 2019;56:100980. [DOI: 10.1016/j.arr.2019.100980] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
43 Gebru YA, Choi MR, Raja G, Gupta H, Sharma SP, Choi YR, Kim HS, Yoon SJ, Kim DJ, Suk KT. Pathophysiological Roles of Mucosal-Associated Invariant T Cells in the Context of Gut Microbiota-Liver Axis. Microorganisms 2021;9:296. [PMID: 33535703 DOI: 10.3390/microorganisms9020296] [Reference Citation Analysis]
44 Boccella N, Paolillo R, Coretti L, D'Apice S, Lama A, Giugliano G, Schiattarella GG, Cuomo M, d'Aquino I, Cavaliere G, Paciello O, Mollica MP, Mattace Raso G, Esposito G, Lembo F, Perrino C. Transverse aortic constriction induces gut barrier alterations, microbiota remodeling and systemic inflammation. Sci Rep 2021;11:7404. [PMID: 33795775 DOI: 10.1038/s41598-021-86651-y] [Reference Citation Analysis]
45 Zuo K, Li J, Li K, Hu C, Gao Y, Chen M, Hu R, Liu Y, Chi H, Wang H, Qin Y, Liu X, Li S, Cai J, Zhong J, Yang X. Disordered gut microbiota and alterations in metabolic patterns are associated with atrial fibrillation. Gigascience 2019;8:giz058. [PMID: 31149718 DOI: 10.1093/gigascience/giz058] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 15.0] [Reference Citation Analysis]
46 Suk KT, Kim DJ. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2019;13:193-204. [PMID: 30791767 DOI: 10.1080/17474124.2019.1569513] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
47 Tang WHW, Bäckhed F, Landmesser U, Hazen SL. Intestinal Microbiota in Cardiovascular Health and Disease: JACC State-of-the-Art Review. J Am Coll Cardiol 2019;73:2089-105. [PMID: 31023434 DOI: 10.1016/j.jacc.2019.03.024] [Cited by in Crossref: 111] [Cited by in F6Publishing: 107] [Article Influence: 55.5] [Reference Citation Analysis]
48 Spehlmann ME, Rangrez AY, Dhotre DP, Schmiedel N, Chavan N, Bang C, Müller OJ, Shouche YS, Franke A, Frank D, Frey N. Heart Failure Severity Closely Correlates with Intestinal Dysbiosis and Subsequent Metabolomic Alterations. Biomedicines 2022;10:809. [DOI: 10.3390/biomedicines10040809] [Reference Citation Analysis]
49 Li J, Yang X, Zhou X, Cai J. The Role and Mechanism of Intestinal Flora in Blood Pressure Regulation and Hypertension Development. Antioxid Redox Signal 2021;34:811-30. [PMID: 32316741 DOI: 10.1089/ars.2020.8104] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
50 Marzullo P, Di Renzo L, Pugliese G, De Siena M, Barrea L, Muscogiuri G, Colao A, Savastano S; Obesity Programs of nutrition, Education, Research and Assessment (OPERA) Group. From obesity through gut microbiota to cardiovascular diseases: a dangerous journey. Int J Obes Suppl 2020;10:35-49. [PMID: 32714511 DOI: 10.1038/s41367-020-0017-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
51 Zhao M, Wei H, Li C, Zhan R, Liu C, Gao J, Yi Y, Cui X, Shan W, Ji L, Pan B, Cheng S, Song M, Sun H, Jiang H, Cai J, Garcia-Barrio MT, Chen YE, Meng X, Dong E, Wang DW, Zheng L. Gut microbiota production of trimethyl-5-aminovaleric acid reduces fatty acid oxidation and accelerates cardiac hypertrophy. Nat Commun 2022;13:1757. [PMID: 35365608 DOI: 10.1038/s41467-022-29060-7] [Reference Citation Analysis]
52 Tang WHW, Li DY, Hazen SL. Dietary metabolism, the gut microbiome, and heart failure. Nat Rev Cardiol 2019;16:137-54. [PMID: 30410105 DOI: 10.1038/s41569-018-0108-7] [Cited by in Crossref: 146] [Cited by in F6Publishing: 136] [Article Influence: 73.0] [Reference Citation Analysis]
53 Althubiani AS, Al-ghamdi SB, Samreen, Qais FA, Khan MS, Ahmad I, Malak HA. Plant-Derived Prebiotics and Its Health Benefits. New Look to Phytomedicine. Elsevier; 2019. pp. 63-88. [DOI: 10.1016/b978-0-12-814619-4.00004-5] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
54 Branchereau M, Burcelin R, Heymes C. The gut microbiome and heart failure: A better gut for a better heart. Rev Endocr Metab Disord 2019;20:407-14. [PMID: 31705258 DOI: 10.1007/s11154-019-09519-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
55 Li Q, Larouche-Lebel É, Loughran KA, Huh TP, Suchodolski JS, Oyama MA. Gut Dysbiosis and Its Associations with Gut Microbiota-Derived Metabolites in Dogs with Myxomatous Mitral Valve Disease. mSystems 2021;6:e00111-21. [PMID: 33879495 DOI: 10.1128/mSystems.00111-21] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
56 Zuo K, Li J, Wang P, Liu Y, Liu Z, Yin X, Liu X, Yang X. Duration of Persistent Atrial Fibrillation Is Associated with Alterations in Human Gut Microbiota and Metabolic Phenotypes. mSystems 2019;4:e00422-19. [PMID: 31822598 DOI: 10.1128/mSystems.00422-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
57 Zuo K, Liu X, Wang P, Jiao J, Han C, Liu Z, Yin X, Li J, Yang X. Metagenomic data-mining reveals enrichment of trimethylamine-N-oxide synthesis in gut microbiome in atrial fibrillation patients. BMC Genomics 2020;21:526. [PMID: 32731896 DOI: 10.1186/s12864-020-06944-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
58 Zhao Z, Liu J, Hu Y, Zhang X, Cao L, Dong Z, Li L, Hu Z. Bacterial diversity in the intestinal mucosa of heart failure rats treated with Sini Decoction. BMC Complement Med Ther 2022;22:93. [PMID: 35354453 DOI: 10.1186/s12906-022-03575-4] [Reference Citation Analysis]
59 Eom JA, Kwon GH, Kim NY, Park EJ, Won SM, Jeong JJ, Raja G, Gupta H, Asmelash Gebru Y, Sharma S, Choi YR, Kim HS, Yoon SJ, Hyun JY, Jeong MK, Park HJ, Min BH, Choi MR, Kim DJ, Suk KT. Diet-Regulating Microbiota and Host Immune System in Liver Disease. Int J Mol Sci 2021;22:6326. [PMID: 34199182 DOI: 10.3390/ijms22126326] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Jia Q, Wang L, Zhang X, Ding Y, Li H, Yang Y, Zhang A, Li Y, Lv S, Zhang J. Prevention and treatment of chronic heart failure through traditional Chinese medicine: Role of the gut microbiota. Pharmacol Res 2020;151:104552. [PMID: 31747557 DOI: 10.1016/j.phrs.2019.104552] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
61 Wen J, Li R, Wang J, Hao J, Qin W, Yang T, Wang R, Wei S, Liu X, Li H, Wang J, Liu H, Zhao Y. Therapeutic effects of Aconiti Lateralis Radix Praeparata combined with Zingiberis Rhizoma on doxorubicin-induced chronic heart failure in rats based on an integrated approach. Journal of Pharmacy and Pharmacology 2020;72:279-93. [DOI: 10.1111/jphp.13191] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
62 Jin L, Shi X, Yang J, Zhao Y, Xue L, Xu L, Cai J. Gut microbes in cardiovascular diseases and their potential therapeutic applications. Protein Cell 2021;12:346-59. [PMID: 32989686 DOI: 10.1007/s13238-020-00785-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Kirschner SK, Deutz NEP, Rijnaarts I, Smit TJ, Larsen DJ, Engelen MPKJ. Impaired intestinal function is associated with lower muscle and cognitive health and well-being in patients with congestive heart failure. JPEN J Parenter Enteral Nutr 2021. [PMID: 34021600 DOI: 10.1002/jpen.2193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Suganya K, Son T, Kim KW, Koo BS. Impact of gut microbiota: How it could play roles beyond the digestive system on development of cardiovascular and renal diseases. Microb Pathog 2021;152:104583. [PMID: 33164814 DOI: 10.1016/j.micpath.2020.104583] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
65 Gesper M, Nonnast ABH, Kumowski N, Stoehr R, Schuett K, Marx N, Kappel BA. Gut-Derived Metabolite Indole-3-Propionic Acid Modulates Mitochondrial Function in Cardiomyocytes and Alters Cardiac Function. Front Med (Lausanne) 2021;8:648259. [PMID: 33829028 DOI: 10.3389/fmed.2021.648259] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
66 Przerwa F, Kukowka A, Kotrych K, Uzar I. Probiotics in prevention and treatment of cardiovascular diseases. Herba Polonica 2021;67:77-85. [DOI: 10.2478/hepo-2021-0026] [Reference Citation Analysis]
67 Seo J, Matthewman L, Xia D, Wilshaw J, Chang YM, Connolly DJ. The gut microbiome in dogs with congestive heart failure: a pilot study. Sci Rep 2020;10:13777. [PMID: 32792610 DOI: 10.1038/s41598-020-70826-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
68 Mallick H, Franzosa EA, Mclver LJ, Banerjee S, Sirota-Madi A, Kostic AD, Clish CB, Vlamakis H, Xavier RJ, Huttenhower C. Predictive metabolomic profiling of microbial communities using amplicon or metagenomic sequences. Nat Commun 2019;10:3136. [PMID: 31316056 DOI: 10.1038/s41467-019-10927-1] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 18.3] [Reference Citation Analysis]
69 Khomtchouk BB, Tran DT, Vand KA, Might M, Gozani O, Assimes TL. Cardioinformatics: the nexus of bioinformatics and precision cardiology. Brief Bioinform 2020;21:2031-51. [PMID: 31802103 DOI: 10.1093/bib/bbz119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Zuo K, Li J, Xu Q, Hu C, Gao Y, Chen M, Hu R, Liu Y, Chi H, Yin Q, Cao Y, Wang P, Qin Y, Liu X, Zhong J, Cai J, Li K, Yang X. Dysbiotic gut microbes may contribute to hypertension by limiting vitamin D production. Clin Cardiol 2019;42:710-9. [PMID: 31099039 DOI: 10.1002/clc.23195] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
71 Schernthaner G, Brand K, Bailey CJ. Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure. Metabolism 2022. [DOI: 10.1016/j.metabol.2022.155160] [Reference Citation Analysis]
72 Le Bastard Q, Ward T, Sidiropoulos D, Hillmann BM, Chun CL, Sadowsky MJ, Knights D, Montassier E. Fecal microbiota transplantation reverses antibiotic and chemotherapy-induced gut dysbiosis in mice. Sci Rep 2018;8:6219. [PMID: 29670191 DOI: 10.1038/s41598-018-24342-x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 11.0] [Reference Citation Analysis]
73 Zhao Y, Wang Z. Gut microbiome and cardiovascular disease. Curr Opin Cardiol 2020;35:207-18. [PMID: 32068612 DOI: 10.1097/HCO.0000000000000720] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
74 Jiang T, Xing X, Zhang L, Liu Z, Zhao J, Liu X. Chitosan Oligosaccharides Show Protective Effects in Coronary Heart Disease by Improving Antioxidant Capacity via the Increase in Intestinal Probiotics. Oxid Med Cell Longev 2019;2019:7658052. [PMID: 30984339 DOI: 10.1155/2019/7658052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
75 Ortega-Hernández A, Martínez-Martínez E, Gómez-Gordo R, López-Andrés N, Fernández-Celis A, Gutiérrrez-Miranda B, Nieto ML, Alarcón T, Alba C, Gómez-Garre D, Cachofeiro V. The Interaction between Mitochondrial Oxidative Stress and Gut Microbiota in the Cardiometabolic Consequences in Diet-Induced Obese Rats. Antioxidants (Basel) 2020;9:E640. [PMID: 32708095 DOI: 10.3390/antiox9070640] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
76 Qin Q, Yan S, Yang Y, Chen J, Li T, Gao X, Yan H, Wang Y, Wang J, Wang S, Ding S. A Metagenome-Wide Association Study of the Gut Microbiome and Metabolic Syndrome. Front Microbiol 2021;12:682721. [PMID: 34335505 DOI: 10.3389/fmicb.2021.682721] [Reference Citation Analysis]
77 Li W, Huang A, Zhu H, Liu X, Huang X, Huang Y, Cai X, Lu J, Huang Y. Gut microbiota‐derived trimethylamine N ‐oxide is associated with poor prognosis in patients with heart failure. Medical Journal of Australia 2020;213:374-9. [DOI: 10.5694/mja2.50781] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
78 Oliphant K, Allen-Vercoe E. Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health. Microbiome 2019;7:91. [PMID: 31196177 DOI: 10.1186/s40168-019-0704-8] [Cited by in Crossref: 216] [Cited by in F6Publishing: 199] [Article Influence: 72.0] [Reference Citation Analysis]
79 Mayneris-Perxachs J, Fernández-Real JM. Exploration of the microbiota and metabolites within body fluids could pinpoint novel disease mechanisms. FEBS J 2020;287:856-65. [PMID: 31709683 DOI: 10.1111/febs.15130] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
80 Ionescu RF, Enache RM, Cretoiu SM, Cretoiu D. The Interplay Between Gut Microbiota and miRNAs in Cardiovascular Diseases. Front Cardiovasc Med 2022;9:856901. [DOI: 10.3389/fcvm.2022.856901] [Reference Citation Analysis]
81 Mollar A, Marrachelli VG, Núñez E, Monleon D, Bodí V, Sanchis J, Navarro D, Núñez J. Bacterial metabolites trimethylamine N-oxide and butyrate as surrogates of small intestinal bacterial overgrowth in patients with a recent decompensated heart failure. Sci Rep 2021;11:6110. [PMID: 33731747 DOI: 10.1038/s41598-021-85527-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Trøseid M, Andersen GØ, Broch K, Hov JR. The gut microbiome in coronary artery disease and heart failure: Current knowledge and future directions. EBioMedicine 2020;52:102649. [PMID: 32062353 DOI: 10.1016/j.ebiom.2020.102649] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 19.5] [Reference Citation Analysis]
83 Onyszkiewicz M, Jaworska K, Ufnal M. Short chain fatty acids and methylamines produced by gut microbiota as mediators and markers in the circulatory system. Exp Biol Med (Maywood) 2020;245:166-75. [PMID: 31948289 DOI: 10.1177/1535370219900898] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
84 Gutiérrez-Calabrés E, Ortega-Hernández A, Modrego J, Gómez-Gordo R, Caro-Vadillo A, Rodríguez-Bobada C, González P, Gómez-Garre D. Gut Microbiota Profile Identifies Transition From Compensated Cardiac Hypertrophy to Heart Failure in Hypertensive Rats. Hypertension 2020;76:1545-54. [PMID: 32921194 DOI: 10.1161/HYPERTENSIONAHA.120.15123] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
85 Vlasov AA, Shperling MI, Terkin DA, Bystrova OV, Osipov GA, Salikova SP, Grinevich VB. Effect of Prebiotic Complex on Gut Microbiota and Endotoxemia in Female Rats with Modeled Heart Failure. Bull Exp Biol Med 2020;168:435-8. [PMID: 32146625 DOI: 10.1007/s10517-020-04726-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Lee NY, Yoon SJ, Han DH, Gupta H, Youn GS, Shin MJ, Ham YL, Kwak MJ, Kim BY, Yu JS, Lee DY, Park TS, Park SH, Kim BK, Joung HC, Choi IS, Hong JT, Kim DJ, Han SH, Suk KT. Lactobacillus and Pediococcus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome. Gut Microbes 2020;11:882-99. [PMID: 31965894 DOI: 10.1080/19490976.2020.1712984] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
87 Koszewicz M, Jaroch J, Brzecka A, Ejma M, Budrewicz S, Mikhaleva LM, Muresanu C, Schield P, Somasundaram SG, Kirkland CE, Avila-Rodriguez M, Aliev G. Dysbiosis is one of the risk factor for stroke and cognitive impairment and potential target for treatment. Pharmacol Res 2021;164:105277. [PMID: 33166735 DOI: 10.1016/j.phrs.2020.105277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
88 Coletto E, Latousakis D, Pontifex MG, Crost EH, Vaux L, Perez Santamarina E, Goldson A, Brion A, Hajihosseini MK, Vauzour D, Savva GM, Juge N. The role of the mucin-glycan foraging Ruminococcus gnavus in the communication between the gut and the brain. Gut Microbes 2022;14:2073784. [PMID: 35579971 DOI: 10.1080/19490976.2022.2073784] [Reference Citation Analysis]
89 Hu Y, Pan Z, Huang Z, Li Y, Han N, Zhuang X, Peng H, Gao Q, Wang Q, Yang Lee BJ, Zhang H, Yang R, Bi Y, Xu ZZ. Gut Microbiome-Targeted Modulations Regulate Metabolic Profiles and Alleviate Altitude-Related Cardiac Hypertrophy in Rats. Microbiol Spectr 2022;:e0105321. [PMID: 35138162 DOI: 10.1128/spectrum.01053-21] [Reference Citation Analysis]
90 Wu PH, Liu PY, Chiu YW, Hung WC, Lin YT, Lin TY, Hung SC, Delicano RA, Kuo MC, Wu CY. Comparative Gut Microbiome Differences between Ferric Citrate and Calcium Carbonate Phosphate Binders in Patients with End-Stage Kidney Disease. Microorganisms 2020;8:E2040. [PMID: 33419265 DOI: 10.3390/microorganisms8122040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
91 Emoto T, Hayashi T, Tabata T, Yamashita T, Watanabe H, Takahashi T, Gotoh Y, Kami K, Yoshida N, Saito Y, Tanaka H, Matsumoto K, Hayashi T, Yamada T, Hirata KI. Metagenomic analysis of gut microbiota reveals its role in trimethylamine metabolism in heart failure. Int J Cardiol 2021;338:138-42. [PMID: 34102245 DOI: 10.1016/j.ijcard.2021.06.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Chaikijurajai T, Tang WHW. Gut Microbiome and Precision Nutrition in Heart Failure: Hype or Hope? Curr Heart Fail Rep 2021;18:23-32. [DOI: 10.1007/s11897-021-00503-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
93 Ahmad AF, Ward NC, Dwivedi G. The gut microbiome and heart failure. Current Opinion in Cardiology 2019;34:225-32. [DOI: 10.1097/hco.0000000000000598] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
94 Yamashita T, Yoshida N, Emoto T, Saito Y, Hirata KI. Two Gut Microbiota-Derived Toxins Are Closely Associated with Cardiovascular Diseases: A Review. Toxins (Basel) 2021;13:297. [PMID: 33921975 DOI: 10.3390/toxins13050297] [Reference Citation Analysis]
95 Mamic P, Chaikijurajai T, Tang WHW. Gut microbiome - A potential mediator of pathogenesis in heart failure and its comorbidities: State-of-the-art review. J Mol Cell Cardiol 2021;152:105-17. [PMID: 33307092 DOI: 10.1016/j.yjmcc.2020.12.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
96 Awoyemi A, Mayerhofer C, Felix AS, Hov JR, Moscavitch SD, Lappegård KT, Hovland A, Halvorsen S, Halvorsen B, Gregersen I, Svardal A, Berge RK, Hansen SH, Götz A, Holm K, Aukrust P, Åkra S, Seljeflot I, Solheim S, Lorenzo A, Gullestad L, Trøseid M, Broch K. Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial. EBioMedicine 2021;70:103511. [PMID: 34329947 DOI: 10.1016/j.ebiom.2021.103511] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Zuo K, Yin X, Li K, Zhang J, Wang P, Jiao J, Liu Z, Liu X, Liu J, Li J, Yang X. Different Types of Atrial Fibrillation Share Patterns of Gut Microbiota Dysbiosis. mSphere 2020;5:e00071-20. [PMID: 32188747 DOI: 10.1128/mSphere.00071-20] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
98 Stefia LV, Lee J, Patel J, de Sousa SR, Legrand J, Rodero M, Burman S, Linedale R, Morrison M, Khosrotehrani K. Secretome Components from Faecalibacterium prausnitzii Strains A2-165 and AHMP21 Modulate Cutaneous Wound Inflammation. J Invest Dermatol 2020;140:2312-2315.e6. [PMID: 32247858 DOI: 10.1016/j.jid.2020.02.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
99 Mayerhofer CCK, Kummen M, Holm K, Broch K, Awoyemi A, Vestad B, Storm-Larsen C, Seljeflot I, Ueland T, Bohov P, Berge RK, Svardal A, Gullestad L, Yndestad A, Aukrust P, Hov JR, Trøseid M. Low fibre intake is associated with gut microbiota alterations in chronic heart failure. ESC Heart Fail 2020;7:456-66. [PMID: 31978943 DOI: 10.1002/ehf2.12596] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
100 Li H, Xu H, Li Y, Jiang Y, Hu Y, Liu T, Tian X, Zhao X, Zhu Y, Wang S, Zhang C, Ge J, Wang X, Wen H, Bai C, Sun Y, Song L, Zhang Y, Hui R, Cai J, Chen J. Alterations of gut microbiota contribute to the progression of unruptured intracranial aneurysms. Nat Commun 2020;11:3218. [PMID: 32587239 DOI: 10.1038/s41467-020-16990-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
101 Formiga F, Ferreira Teles CI, Chivite D. Impact of intestinal microbiota in patients with heart failure: A systematic review. Med Clin (Barc) 2019;153:402-9. [PMID: 31416611 DOI: 10.1016/j.medcli.2019.06.006] [Reference Citation Analysis]
102 Luedde M, Spehlmann ME, Frey N. Progress in heart failure treatment in Germany. Clin Res Cardiol 2018;107:105-13. [DOI: 10.1007/s00392-018-1317-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
103 Bartolomaeus H, McParland V, Wilck N. [Gut-heart axis : How gut bacteria influence cardiovascular diseases]. Herz 2020;45:134-41. [PMID: 32077981 DOI: 10.1007/s00059-020-04897-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Strati F, Lattanzi G, Amoroso C, Facciotti F. Microbiota-targeted therapies in inflammation resolution. Semin Immunol 2022;:101599. [PMID: 35304068 DOI: 10.1016/j.smim.2022.101599] [Reference Citation Analysis]
105 Partula V, Deschasaux-Tanguy M, Mondot S, Victor-Bala A, Bouchemal N, Lécuyer L, Bobin-Dubigeon C, Torres MJ, Kesse-Guyot E, Charbit B, Patin E, Assmann KE, Latino-Martel P, Julia C, Galan P, Hercberg S, Quintana-Murci L, Albert ML, Duffy D, Lantz O, Savarin P, Triba MN, Touvier M; Milieu Intérieur Consortium. Associations between untargeted plasma metabolomic signatures and gut microbiota composition in the Milieu Intérieur population of healthy adults. Br J Nutr 2020;:1-11. [PMID: 33298217 DOI: 10.1017/S0007114520004870] [Reference Citation Analysis]
106 Lv S, Wang Y, Zhang W, Shang H. Trimethylamine oxide: a potential target for heart failure therapy. Heart 2021:heartjnl-2021-320054. [PMID: 34611047 DOI: 10.1136/heartjnl-2021-320054] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Kumar D, Mukherjee SS, Chakraborty R, Roy RR, Pandey A, Patra S, Dey S. The emerging role of gut microbiota in cardiovascular diseases. Indian Heart J 2021;73:264-72. [PMID: 34154741 DOI: 10.1016/j.ihj.2021.04.008] [Reference Citation Analysis]
108 Gerdes V, Gueimonde M, Pajunen L, Nieuwdorp M, Laitinen K. How strong is the evidence that gut microbiota composition can be influenced by lifestyle interventions in a cardio-protective way? Atherosclerosis 2020;311:124-42. [PMID: 32981713 DOI: 10.1016/j.atherosclerosis.2020.08.028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]